How do rapid antigen tests compare to PCR tests for public health?

PCR tests are analytically more sensitive, detecting even one viral molecule, which is useful for diagnosing infection but can remain positive for weeks after contagiousness. Rapid antigen tests, while less sensitive analytically, are highly sensitive for detecting high viral loads, which correlates with infectiousness, making them superior for public health goals of preventing onward transmission quickly.

Why aren't rapid at-home COVID tests widely available in the United States?

The main reason is that the FDA classifies these tests as medical devices and evaluates them against PCR as a gold standard for diagnosis, not for public health purposes of detecting infectiousness. This misunderstanding of their public health utility slows down authorization and market entry.

How can the regulatory bottleneck for rapid tests be resolved?

Michael Mina proposes that the President of the United States should use executive powers to designate rapid antigen tests as 'public health tools' rather than medical devices. This would allow organizations like the CDC to certify them based on appropriate public health metrics, similar to how the UK rapidly deployed them.

Do we still need rapid tests if we have COVID-19 vaccines?

Yes. Vaccines primarily aim to stop severe disease, not necessarily transmission, and their efficacy against transmission can wane or be challenged by new variants like Delta. Rapid tests are essential to stop transmission, especially among vaccinated individuals who can still spread the virus, and to prevent the virus from mutating further.

What would an ideal dynamic COVID-19 testing program look like?

Every household would have tests at home. Testing frequency would be adjusted based on community viral load, potentially monitored via wastewater. If cases rise, people would be asked to test more frequently (e.g., daily or every two days) to quickly identify and squash outbreaks, rather than a constant, rigid testing schedule.

How can rapid test results be verified while preserving privacy?

Services like eMed provide proctored at-home testing via phone or computer, generating verified laboratory reports. While current regulations may require reporting to public health agencies, systems could be developed (e.g., for over-the-counter tests not bound by CLIA rules) to offer individuals the option to opt-in or out of centralized reporting, giving them more control over their data.

What are the concerns with President Biden's 'vaccinate or test' policy?

The policy risks politicizing testing, which was previously bipartisan. It's confusing because vaccinated individuals can still transmit the virus, making the 'or' problematic for public health. It also creates massive demand for testing that current supply chains, under FDA regulations, cannot meet, potentially leading to another testing crisis.

How does testing reduce COVID-19-related anxiety?

Testing provides crucial information, transforming the problem of uncertainty into one of data. When people know their infectious status quickly, they feel empowered to make informed decisions, reducing fear of unknowingly spreading the virus and allowing for more relaxed social interactions in tested environments, ultimately improving mental well-being.

What is the 'end game' for the COVID-19 pandemic according to Michael Mina?

The end game involves human civilization 'growing out of' the virus, similar to how babies build diverse immunity over time through multiple exposures and vaccinations. Over several years, immunity will strengthen across the population, making the virus less dangerous for most, though still a concern for the elderly.

What practical steps can individuals take to advocate for rapid testing policy changes?

Individuals should generate noise on social media and in traditional media, emphasizing that 'a public health test is a public health tool.' They should also contact politicians and lobbyists to request that the President use executive powers to designate rapid tests as public health tools, enabling faster CDC authorization.

Key Moments

Michael Mina: Rapid COVID Testing | Lex Fridman Podcast #235

Lex Fridman

Science & Technology3 min read107 min video

Oct 29, 2021|60,515 views|1,498|198

Harvard agi ai ai podcast antigen test artificial intelligence artificial intelligence podcast coronavirus covid epidemiology immunology lex ai

Save to Pod

Key Moments

TL;DR

Rapid at-home COVID tests are crucial public health tools, hindered by regulatory and medical device classifications.

Key Insights

Rapid at-home antigen tests are highly effective at detecting contagiousness, which is the key public health metric.

The FDA's classification of rapid tests as medical devices, evaluated against sensitive PCR tests, impedes their widespread adoption.

A public health pathway for test authorization, distinct from medical device regulation, is needed.

The Biden administration's 'vaccinate or test' approach, while encouraging testing, could overwhelm PCR labs and politicize testing.

Vaccines are effective at preventing severe illness but not at stopping transmission, underscoring the continued need for rapid testing.

Dynamic, community-level testing programs, guided by wastewater surveillance and individual empowerment, are a more effective strategy than rigid mandates.

THE OVERLOOKED SOLUTION: RAPID AT-HOME TESTING

Michael Mina argues that rapid at-home COVID-19 tests have been the most obvious and powerful solution to the pandemic since its inception. These tests, unlike PCR tests, are designed to detect contagiousness by identifying high viral loads. Their accessibility, affordability, and speed empower individuals with crucial information about their infectious status, enabling them to make informed decisions to protect themselves and others, all while preserving privacy and freedom.

MISUNDERSTANDING TEST UTILITY: MEDICAL DEVICE VS. PUBLIC HEALTH TOOL

A central obstacle to the widespread adoption of rapid tests is their classification by the FDA as medical devices, evaluated for diagnostic sensitivity against PCR. Physicians, trained for individual patient care, prioritize highly sensitive tests that detect any viral presence, even non-infectious stages. However, for public health, the critical question is infectiousness, which rapid antigen tests accurately identify, providing timely results essential for preventing transmission.

THE NEED FOR A PUBLIC HEALTH TESTING PATHWAY

The current regulatory framework, focused on medical device evaluation, does not accommodate the unique needs of public health testing. The FDA's stringent requirements, comparing rapid tests to PCR's analytical sensitivity, create an impossible standard for tests that are, by design, more attuned to infectiousness. Mina advocates for a parallel public health pathway, potentially led by the CDC, to authorize and evaluate tests based on their utility in controlling community spread, not just individual diagnosis.

VACCINES AND THE CONTINUED ROLE OF TESTING

While vaccines are crucial for preventing severe illness, they do not completely halt transmission, especially with the emergence of variants and waning immunity. Breakthrough infections can and do occur, meaning vaccinated individuals can still spread the virus. This limitation highlights the continued necessity of rapid testing to identify and isolate infectious individuals, regardless of vaccination status, to effectively manage the pandemic.

DYNAMIC TESTING STRATEGIES FOR COMMUNITY MANAGEMENT

Instead of broad mandates, Mina proposes dynamic testing programs tailored to community transmission levels. This includes maintaining readily available at-home tests, utilizing wastewater surveillance to monitor viral presence, and escalating testing frequency in affected areas. This approach empowers individuals to test when necessary, rather than enforcing continuous testing, optimizing resource use and fostering community cooperation.

ADDRESSING ACCESS, PRIVACY, AND POLICY FAILURES

The Biden administration's plan to increase rapid test availability and mandate them in workplaces is a step forward, but a pledge of 280 million tests is insufficient for the US population. The 'vaccinate or test' policy is also criticized for potentially politicizing testing and implicitly suggesting vaccines fully prevent transmission. Mina stresses the importance of transparent communication, ensuring access, and developing systems that verify test results while respecting individual privacy, allowing people to opt-in for public health reporting.

THE INFORMATION PROBLEM: UNCERTAINTY AND FEAR

COVID-19's spread is fundamentally an information problem, exacerbated by uncertainty. Quarantine and isolation measures were implemented because of a lack of real-time information about infectiousness. Rapid tests provide this critical information, reducing fear and empowering individuals to make safer choices. By providing clear data, testing can move society away from blanket restrictions towards targeted interventions, fostering a sense of control and reducing anxiety.

THE PATH FORWARD: ACTIVISM AND POLICY CHANGE

Mina emphasizes that individual action, such as advocating for policy changes and demanding access to testing, is crucial. He calls for leveraging executive powers to designate rapid tests as public health tools, distinct from medical devices, and empowering agencies like the CDC to streamline their authorization. This shift would allow for the rapid deployment of widely available, affordable tests, fundamentally changing the approach to managing the pandemic and future public health challenges.

Mentioned in This Episode

●Software & Apps

●Companies

●Organizations

●Concepts

●People Referenced

Common Questions

Rapid at-home tests are simple paper strip tests that involve swabbing the front of the nose, placing the swab in a liquid tube, and then putting a few drops of the liquid onto the strip. In about 10 minutes, two lines indicate positive, and one line indicates negative. They are highly effective at determining if someone is currently infectious.

Topics

Health & Longevity Mental Health & Psychology Pandemic Response Public Health Policy PCR Testing FDA Regulation Vaccine Efficacy Medicine & Clinical Politics & Policy COVID-19 Testing Rapid Antigen Tests Dynamic Testing Strategies

Mentioned in this video

People

Michael Mina

Professor at Harvard doing research on infectious disease and immunology, advocating for rapid at-home COVID testing.

Sundar Pichai

CEO of Google, mentioned as a powerful figure who could influence governments and large-scale manufacturing of rapid tests.

Donald Trump

Mentioned as the president during early discussions about rapid testing, where plans to deploy tests faced political hurdles.

Jim Keller

An engineer known for his work in processor design, mentioned as a former Tesla employee who understands efficient manufacturing.

Sam Harris

A neuroscientist and author who discusses the ability to escape the sense of free will and agency through meditation.

Elon Musk

Suggested as someone who could apply Tesla's world-class manufacturing efficiency to produce rapid tests at massive scale and lower cost.

Francis Collins

Director of the National Institutes of Health, mentioned as attending a conference where daily rapid testing was implemented.

Organizations

CDC

The public health agency that Michael Mina believes should take over the authorization and certification of public health testing tools if designated by executive action.

TSA

The agency that accepts eMed-verified rapid antigen tests for entry into the United States.

CVS

A pharmacy chain where rapid at-home COVID tests are available for purchase.

The Atlantic

A publication where Michael Mina wrote an article titled 'Here's a Plan to Give Us Our Lives Back' advocating for rapid testing.

New York Times

A publication where Michael Mina wrote an op-ed arguing for the continued need for rapid tests alongside vaccines.

Mike Milken Institute

An organization that hosts conferences where attendees are required to take rapid tests daily, showcasing effective use of verified at-home testing.

FDA

The regulatory body that classifies rapid tests as medical devices, leading to stringent authorization processes ill-suited for public health tools.

NIH

Mentioned as a potential entity, alongside the CDC or academic centers, to evaluate and authorize rapid tests for public health use.

Locations

Germany

A country with high market competition and many authorized rapid tests, leading to very low costs of under a dollar per test.

United Kingdom

Cited as an example of a country that successfully evaluated and deployed rapid antigen tests quickly by treating them as public health tools outside of traditional medical diagnostic regulatory agencies.

Sri Lanka

The country where Michael Mina was living as a Buddhist monk when the 2004 Indian Ocean Tsunami occurred.

Heathrow Airport

Mentioned as a location where international travelers can use eMed for rapid antigen test verification before flying to the United States.

Software & Apps

rapidtest.org

A website developed to automate the process of writing letters to congressional members and elected representatives in support of rapid testing.

Rapid Antigen Test

Paper strip tests designed to quickly determine if someone is currently infectious, ideal for public health purposes and at-home use due to speed and accessibility.

PCR test

A laboratory-based test for COVID-19, known for its high analytical sensitivity but often slow turnaround time, making it less suitable for public health screening for infectiousness.

Wastewater Testing for SARS-CoV-2

A surveillance method to monitor the prevalence of the virus in a community by detecting viral RNA in wastewater, used to inform dynamic testing strategies.

Concepts

COVID-19

The infectious disease that is the central topic of discussion, with specific focus on solutions like rapid at-home testing.

CMS

An agency that designates tests as medical devices if they can alter human behavior based on results, contributing to the regulatory bottleneck.

Delta variant

A variant of COVID-19 that significantly impacted vaccine efficacy against transmission, highlighting the ongoing need for rapid testing.

Nirvana

The ultimate goal for a Buddhist monk, characterized by an absence of any attachment, even to oneself.

Buddhism

A philosophy and religion that emphasizes meditation, detachment, and achieving nirvana, which Michael Mina studied as a monk.

Companies

Amazon

An online retailer where rapid tests are expected to be available, but concerns are raised about potential stock shortages due to increased demand.

Walgreens

A pharmacy chain where rapid at-home COVID tests are available for purchase.

eMed

A service that provides verified test proctoring and generates authenticated laboratory reports for at-home rapid tests, used by the CDC for international travel.

Ginkgo Bioworks

A company based in Cambridge working with numerous labs to conduct pooled testing for millions of children, demonstrating a different regulatory approach.

Tesla

Elon Musk's company, cited for its expertise in manufacturing goods much cheaper and better, a model for rapid test production.

Samsara

In Buddhist thought, the cycle of rebirth and suffering that attachments are believed to perpetuate.

Media

Lex Fridman Podcast

The podcast platform hosting this conversation, with Michael Mina making his second appearance.

Wall Street Journal

A publication where Michael Mina wrote an op-ed arguing for the continued need for rapid tests alongside vaccines.

Legislation & Policy

Biden COVID-19 Action Plan

A plan introduced by President Biden, prominently featuring testing and scaling up rapid tests as key pillars.

CLIA

Regulations that govern laboratory testing; eMed is considered a CLIA-waived laboratory, meaning it is legally bound to report test results to public health agencies.